cdk13 inhibitor sr  (Selleck Chemicals)

Journal: BMC Biology

Article Title: ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner

doi: 10.1186/s12915-024-01927-9

Figure Lengend Snippet: The CDK13 gene is edited by ADAR1 and ARID1A deficiency increased sensitivity to SR4835. A Comparison of HCT116 shARID1A to ARID1A_Scramble cell lines. The differential genes in “RNA editing” category consists of ARL6IP4, BLCAP, COPA, CDK13, and NEIL1. B The RNA editing frequency at different sites of COPA, BLCAP, ARL6IP4 genes in HCT116 ARID1A_WT, ARID1A_KO, ARID1A_KO + shADAR#1, and ARID1A_KO + shADAR#2 cell lines. C The RNA editing frequency at three different sites of CDK13 genes in HCT116 ARID1A_WT, ARID1A_KO, ARID1A_KO + shADAR#1, and ARID1A_KO + shADAR#2 cell lines. D RT-qPCR results show ADAR mRNA expression in HCT116 ARID1A_KO, ARID1A_KO + shADAR#1, and ARID1A_KO + shADAR#2 cell lines. n = 3; mean ± SD; *, P < 0.05; ns, not significant. E Diagram of the CDK13 kinase, showing the serine/threonine protein kinase active region. Intron regions and three RNA editing sites (K21R, K117R, and Q113R) are marked. K21R:7_39990302; K117R:7_39990590; Q113R: 7_39990578. Exported by "SMART" software, the red line represents intron Phase 2 and the blue line represents intron Phase 1. F Representative images of A375 Scramble and shARID1A cells treated with SR-4835 at a concentration of 1 nM and 10 nM. G Quantitative results represent the mean ± SD of three independent experiments. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001. H Representative images of HCT116 Scramble and shARID1A cells treated with SR-4835 at a concentration of 1 nM and 10 nM. I Quantitative results represent the mean ± SD of three independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001

Article Snippet: The CDK13 inhibitor SR-4835 was purchased from Selleckchem (Houston, USA).

Techniques: Comparison, Quantitative RT-PCR, Expressing, Software, Concentration Assay

Journal: BMC Biology

Article Title: ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner

doi: 10.1186/s12915-024-01927-9

Figure Lengend Snippet: ADAR1 edits CDK13 at position Q113R and K117R, ADAR1 knockdown rescues the sensitivity to SR4835. A Sanger sequencing chromatograms using a reverse primer illustrate editing of CDK13 K21R position in ARID1A_WT, ARID1A_KO and genomic DNA (gDNA) in HCT116 cell lines. B Sanger sequencing chromatograms using a reverse primer illustrate editing of CDK13 Q113R position in ARID1A_WT, ARID1A_KO and genomic DNA (gDNA) in HCT116 cell lines. C Sanger sequencing chromatograms using a reverse primer illustrate editing of CDK13 K117R position in ARID1A_WT, ARID1A_KO and genomic DNA (gDNA) in HCT116 cell lines. D Representative images of HCT116_ARID1A_KO cell lines transfected with siNC and siADAR and treatment with SR-4835 at a concentration of 5 nM and 10 nM. E Quantitative results represent the mean ± SD of three independent experiments. **, P < 0.01; ***, P < 0.001. F Representative images of A375_ARID1A_KO cell lines transfected with siNC and siADAR and treatment with SR-4835 at a concentration of 5 nM and 10 nM. G Quantitative results represent the mean ± SD of three independent experiments. *, P < 0.05; **, P < 0.01. H Representative images of DLD-1_ARID1A_KO cell lines transfected with siNC and siADAR and treatment with SR-4835 at a concentration of 5 nM and 10 nM. I Quantitative results represent the mean ± SD of three independent experiments. ***, P < 0.001.****, P < 0.0001

Article Snippet: The CDK13 inhibitor SR-4835 was purchased from Selleckchem (Houston, USA).

Techniques: Knockdown, Sequencing, Transfection, Concentration Assay